Johnson & Johnson

10/19/2025 | Press release | Distributed by Public on 10/19/2025 08:37

Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Johnson & Johnson published this content on October 19, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 19, 2025 at 14:37 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]